Evaluation of cfDNA as an early detection assay for dense tissue breast cancer

• Published in: Scientific reports Vol. 12; no. 1; pp. 8458 - 14
• Main Authors: Barbirou, Mouadh, Miller, Amanda A., Gafni, Erik, Mezlini, Amel, Zidi, Asma, Boley, Nathan, Tonellato, Peter J.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 19.05.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/208; 631/337; 631/67; 692/4017; 692/4028; 692/53; Bioassays; Biopsy; Breast cancer; Carcinogens; Cbfa-1 protein; Copy number; Gene deletion; Genomes; Humanities and Social Sciences; Insertion; Mammography; multidisciplinary; Next-generation sequencing; Science; Science (multidisciplinary); Single-nucleotide polymorphism; Tissues
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-12457-1

A cell-free DNA (cfDNA) assay would be a promising approach to early cancer diagnosis, especially for patients with dense tissues. Consistent cfDNA signatures have been observed for many carcinogens. Recently, investigations of cfDNA as a reliable early detection bioassay have presented a powerful opportunity for detecting dense tissue screening complications early. We performed a prospective study to evaluate the potential of characterizing cfDNA as a central element in the early detection of dense tissue breast cancer (BC). Plasma samples were collected from 32 consenting subjects with dense tissue and positive mammograms, 20 with positive biopsies and 12 with negative biopsies. After screening and before biopsy, cfDNA was extracted, and whole-genome next-generation sequencing (NGS) was performed on all samples. Copy number alteration (CNA) and single nucleotide polymorphism (SNP)/insertion/deletion (Indel) analyses were performed to characterize cfDNA. In the positive-positive subjects (cases), a total of 5 CNAs overlapped with 5 previously reported BC-related oncogenes (KSR2, MAP2K4, MSI2, CANT1 and MSI2). In addition, 1 SNP was detected in KMT2C, a BC oncogene, and 9 others were detected in or near 10 genes (SERAC1, DAGLB, MACF1, NVL, FBXW4, FANK1, KCTD4, CAVIN1; ATP6V0A1 and ZBTB20-AS1) previously associated with non-BC cancers. For the positive–negative subjects (screening), 3 CNAs were detected in BC genes (ACVR2A, CUL3 and PIK3R1), and 5 SNPs were identified in 6 non-BC cancer genes (SNIP1, TBC1D10B, PANK1, PRKCA and RUNX2; SUPT3H). This study presents evidence of the potential of using cfDNA somatic variants as dense tissue BC biomarkers from a noninvasive liquid bioassay for early cancer detection.